Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Clinical observation on therapeutic effect of electroacupuncture combined with diclofenac sodium in treatment of acute gouty arthritis: a randomized controlled study
Liu L, Yin P, Hu J, Li X, Chen Y
Evidence-Based Complementary and Alternative Medicine 2022 (3363064):Epub
clinical trial
6/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: No. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

OBJECTIVE: To observe the clinical effect of electroacupuncture (EA) combined with diclofenac sodium (DS) in the treatment of acute gouty arthritis (AGA). METHODS: Patients with AGA were randomly divided into three groups: the EA plus DS treatment group (ie, EA plus DS group), the low-dose DS treatment group (ie, low-dose DS group), and the conventional-dose DS treatment group (ie, conventional DS group). Patients in the low-dose DS group took 50 mg of DS sustained-release capsules once a day. Patients in the conventional DS group took 100 mg of DS sustained-release capsules once a day. Patients in the EA plus DS group were treated with EA three times in 7 days combined with 50 mg of DS sustained-release capsules once a day. For all the three groups, 7 days were regarded as a course of treatment. Outcome indicators included pain visual analog scale (VAS), joint tenderness, joint swelling and activity limitation, and levels of inflammatory indicators (C-reactive protein (CRP)/white blood cells (WBC)/percentage of neutrophils (NE%)), level of serum uric acid (SUA), gout impact scale (GIS), and frequency of adverse reactions). RESULTS: After a course of treatment, indicators regarding the VAS, joint tenderness, joint swelling, activity limitation, GIS, inflammatory indicators (CRP/WBC/NE%), and SUA were all improved (p < 0.05) with no adverse reactions in the EA plus DS group. The EA plus DS group performed better than the low-dose DS group in improving indicators regarding the VAS, joint tenderness, activity limitation, GIS, inflammatory markers (WBC/NE%), and SUA (p < 0.05). Similarly, the EA plus DS group performed better than the conventional DS group in improving indicators regarding GIS, SUA, and adverse reactions (p < 0.05). CONCLUSION: EA combined with DS can improve AGA patients' joint pain and functional status, thus improving their quality of life. Moreover, this combined treatment can reduce the levels of inflammatory markers and SUA, leading to fewer adverse reactions in AGA patients.

Full text (sometimes free) may be available at these link(s):      help